Health Canada has issued an alert after Gore identified, through quality‑control testing, that a subset of its VIABAHN® endoprosthesis devices were processed using equipment that was operating outside the validated range. This condition could potentially lead to an incorrect bonding location of the distal tip onto the delivery catheter.
Manufacturers and users are advised to review the affected product batches and follow any further guidance from Health Canada regarding corrective actions or product handling.
Regulatory UpdatesSep 4, 2026•1 min read
Gore VIABAHN® Device Quality Issue Identified
Gore discovered some VIABAHN® devices were processed on equipment outside validated range, risking incorrect distal tip bonding.
Compiled by the PharmaCountry team · Source: Health Canada
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating